Anti-pancreatic cancer drug discovery is the need of the hour, because of poor prognosis and low survival rate due to the late detection of the disease. According to a US FDA report, 14% of FDA-approved drugs include pyridine ring system (alpelisib, lorlatinib, pexidartinib, venetoclax, and neratinib), and it's an important heterocycle present in many alkaloids, vitamins, co-enzymes. Consequently, pyridine core scaffolds were fascinating as potent hits over a number of diseases. Hence, some novel pyridine core scaffolds were synthesised by using palladium catalysed Suzuki-Miayura coupling reaction. Further, the generated compounds were screened over MIA PaCa-2 cell line via MTT assay to assess their efficacy as antipancreatic cancer hits. As a result, screened compounds revealed the significant potency over pancreatic cancer cell line (MIA PaCa-2) with desired IC 50 values. On the other hand, in silico study was performed via molecular docking to evaluate their binding efficacy over protein. As a result, the biological results and Insilico studies were complementing each other. In future, the further modification on these molecules may help to investigate new anticancer hits over pancreatic cancer (MIA PaCa-2).